Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
BackgroundHeparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalize...
Main Authors: | Pasquale Paolisso, Luca Bergamaschi, Emanuela Concetta D’Angelo, Francesco Donati, Maddalena Giannella, Sara Tedeschi, Renato Pascale, Michele Bartoletti, Giulia Tesini, Mauro Biffi, Benilde Cosmi, Carmine Pizzi, Pierluigi Viale, Nazzareno Galié |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01124/full |
Similar Items
-
LOW-MOLECULAR WEIGHT HEPARIN (LMWH) AS A PROPHYLAXISOF DEEP VEIN THROMBOSIS (DVT) IN TRAUMATIC PATIENTS
by: Dian Megasafitri, et al.
Published: (2013-07-01) -
Chitosan hydrogels functionalized with either unfractionated heparin or bemiparin improve diabetic wound healing
by: Alberto Cifuentes, et al.
Published: (2020-09-01) -
Anticoagulation in COVID-19: why, what, and when
by: Khaled M Taema
Published: (2021-01-01) -
New Insights in Thrombin Inhibition Structure–Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin
by: Pierre A. J. Mourier, et al.
Published: (2017-03-01) -
Heparin versus enoxaparine for prevention of asymptomatic deep venous thrombosis after total knee arthroplasty
by: Adnan H. Hnoosh, et al.
Published: (2013-01-01)